Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Asset Resilience Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has an Asset Resilience Ratio of 42.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.03 Billion | 42.71% |
| Total Liquid Assets | CN¥1.03 Billion | 42.71% |
Asset Resilience Insights
- Very High Liquidity: Hubei Biocause Heilen Pharmaceutical Co. Ltd. maintains exceptional liquid asset reserves at 42.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Hubei Biocause Heilen Pharmaceutical Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.94% | CN¥1.09 Billion | CN¥2.49 Billion | +38.86pp |
| 2023-12-31 | 5.08% | CN¥129.40 Million | CN¥2.55 Billion | +0.92pp |
| 2022-12-31 | 4.16% | CN¥103.98 Million | CN¥2.50 Billion | -25.72pp |
| 2020-12-31 | 29.88% | CN¥240.00 Million | CN¥803.25 Million | -9.15pp |
| 2019-12-31 | 39.03% | CN¥291.00 Million | CN¥745.56 Million | -- |